

World Journal of *Gastroenterology*

World J Gastroenterol 2017 August 7; 23(29): 5257-5450



EDITORIAL

- 5257 Liver and the defects of cholesterol and bile acids biosynthesis: Rare disorders many diagnostic pitfalls
Corso G, Dello Russo A, Gelzo M

REVIEW

- 5266 Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression
Bacigalupo ML, Carabias P, Troncoso MF
- 5282 From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world
Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, Athanasiou A, Moris D, Sakellariou S, Kykalos S, Tsourouflis G, Garmpi A, Delladetsima I, Kontzoglou K, Kouraklis G

ORIGINAL ARTICLE

Basic Study

- 5295 Partial external biliary diversion in bile salt export pump deficiency: Association between outcome and mutation
Ellinger P, Stindt J, Dröge C, Sattler K, Stross C, Kluge S, Herebian D, Smits SHJ, Burdelski M, Schulz-Jürgensen S, Ballauff A, Schulte am Esch J, Mayatepek E, Häußinger D, Kubitz R, Schmitt L
- 5304 Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
Drmic D, Kolenc D, Ilic S, Bauk L, Sever M, Zenko Sever A, Luetic K, Suran J, Seiwert S, Sikiric P
- 5313 Hwangryunhaedok-tang induces the depolarization of pacemaker potentials through 5-HT₃ and 5-HT₄ receptors in cultured murine small intestine interstitial cells of Cajal
Kim HJ, Lee GS, Kim H, Kim BJ
- 5324 MicroRNA exhibit altered expression in the inflamed colonic mucosa of ulcerative colitis patients
Valmiki S, Ahuja V, Paul J
- 5333 Salvianolic acid B protects hepatocytes from H₂O₂ injury by stabilizing the lysosomal membrane
Yan XF, Zhao P, Ma DY, Jiang YL, Luo JJ, Liu L, Wang XL
- 5345 PBX1 attributes as a determinant of connexin 32 downregulation in *Helicobacter pylori*-related gastric carcinogenesis
Liu XM, Xu CX, Zhang LF, Huang LH, Hu TZ, Li R, Xia XJ, Xu LY, Luo L, Jiang XX, Li M

Case Control Study

- 5356 Influence of dietary isoflavone intake on gastrointestinal symptoms in ulcerative colitis individuals in remission

Gląbska D, Guzek D, Grudzińska D, Lech G

- 5364 Genetic polymorphisms of *MAFK*, encoding a small Maf protein, are associated with susceptibility to ulcerative colitis in Japan

Arisawa T, Nakamura M, Otsuka T, Jing W, Sakurai N, Takano H, Hayashi T, Ota M, Nomura T, Hayashi R, Shimasaki T, Tahara T, Shibata T

Retrospective Study

- 5371 Elaboration and validation of Crohn's disease anoperineal lesions consensual definitions

Horaist C, de Parades V, Abramowitz L, Benfredj P, Bonnaud G, Boucharde D, Fathallah N, Sénéjoux A, Siproudhis L, Staumont G, Viguier M, Marteau P

- 5379 Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma

Miyazaki M, Yada M, Tanaka K, Senjyu T, Goya T, Motomura K, Kohjima M, Kato M, Masumoto A, Kotoh K

- 5386 Outcomes of preoperative endoscopic nasobiliary drainage and endoscopic retrograde biliary drainage for malignant distal biliary obstruction prior to pancreaticoduodenectomy

Zhang GQ, Li Y, Ren YP, Fu NT, Chen HB, Yang JW, Xiao WD

Clinical Trials Study

- 5395 Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma

Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR

Observational Study

- 5405 Transition clinic attendance is associated with improved beliefs and attitudes toward medicine in patients with inflammatory bowel disease

Fu N, Jacobson K, Round A, Evans K, Qian H, Bressler B

- 5412 Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis

Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M

- 5422 Efficacy of forced coagulation with low high-frequency power setting during endoscopic submucosal dissection

Ishida T, Toyonaga T, Ohara Y, Nakashige T, Kitamura Y, Ariyoshi R, Takihara H, Baba S, Yoshizaki T, Kawara F, Tanaka S, Morita Y, Umegaki E, Hoshi N, Azuma T

Prospective Study

- 5431** Clinical outcomes of isolated renal failure compared to other forms of organ failure in patients with severe acute pancreatitis

Gougol A, Dugum M, Dudekula A, Greer P, Slivka A, Whitcomb DC, Yadav D, Papachristou GI

SYSTEMATIC REVIEW

- 5438** Laparoscopic ultrasonography as an alternative to intraoperative cholangiography during laparoscopic cholecystectomy

Dili A, Bertrand C

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Shinji Tanaka, MD, PhD, Professor, Department of Endoscopy, Hiroshima University Hospital, Hiroshima 734-8551, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Dan Li*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
 ISSN 1007-9327 (print)
 ISSN 2219-2840 (online)

LAUNCH DATE
 October 1, 1995

FREQUENCY
 Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
 All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
 Jin-Lei Wang, Director
 Yuan Qi, Vice Director
 Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
 Baishideng Publishing Group Inc
 7901 Stoneridge Drive, Suite 501,
 Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: editorialoffice@wjgnet.com
 Help Desk: <http://www.fpublishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
 Baishideng Publishing Group Inc
 7901 Stoneridge Drive, Suite 501,
 Pleasanton, CA 94588, USA
 Telephone: +1-925-2238242
 Fax: +1-925-2238243
 E-mail: bpgoffice@wjgnet.com
 Help Desk: <http://www.fpublishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
 August 7, 2017

COPYRIGHT
 © 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
 All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
 Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.fpublishing.com>

Case Control Study

Genetic polymorphisms of *MAFK*, encoding a small Maf protein, are associated with susceptibility to ulcerative colitis in Japan

Tomiyasu Arisawa, Masakatsu Nakamura, Toshimi Otsuka, Wu Jing, Naoko Sakurai, Hikaru Takano, Tasuku Hayashi, Masafumi Ota, Tomoe Nomura, Ranji Hayashi, Takeo Shimasaki, Tomomitsu Tahara, Tomoyuki Shibata

Tomiyasu Arisawa, Masakatsu Nakamura, Toshimi Otsuka, Wu Jing, Naoko Sakurai, Hikaru Takano, Tasuku Hayashi, Masafumi Ota, Tomoe Nomura, Ranji Hayashi, Takeo Shimasaki, Department of Gastroenterology, Kanazawa Medical University, Ishikawa 920-0293, Japan

Tomomitsu Tahara, Tomoyuki Shibata, Department of Gastroenterology, Fujita Health University, Kutsukake-cho, Toyoake 470-1192, Japan

Author contributions: Arisawa T analyzed the data, wrote the paper and was responsible for the conception of the study and designed the study; Nakamura M, Otsuka T, Sakurai N, Takano H, Hayashi T, Ota M, Nomura T and Hayashi R obtained the samples and the data; Jing W and Shimasaki T determined genotype; Tahara T and Shibata T participated in the design of the study.

Institutional review board statement: The study was approved by the Ethics Committee of Kanazawa Medical University (Uchinada-machi, Japan) and Fujita Health University (Toyoake, Japan).

Informed consent statement: All patients gave informed consent.

Conflict-of-interest statement: There are no conflicts of interest.

Data sharing statement: Technical appendix, statistical code and dataset available from the corresponding author at tarisawa@kanazawa-med.ac.jp. Informed consent form participants for data sharing was not obtained but the presented data are anonymized and risk of identification is low.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and

the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Tomiyasu Arisawa, MD, PhD, Department of Gastroenterology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Ishikawa 920-0293, Japan. tarisawa@kanazawa-med.ac.jp
Telephone: +81-76-2188154
Fax: +81-76-2860892

Received: January 24, 2017

Peer-review started: February 1, 2017

First decision: March 3, 2014

Revised: March 14, 2014

Accepted: July 4, 2017

Article in press: July 4, 2017

Published online: August 7, 2017

Abstract**AIM**

To investigate whether single nucleotide polymorphisms in maf protein K (*MAFK*), which encodes the *MAFK*, lead to increased susceptibility to ulcerative colitis in the Japanese population.

METHODS

This case control study examined the associations between *MAFK* single nucleotide polymorphisms (rs4268033 G>A, rs3735656 T>C and rs10226620 C>T) and ulcerative colitis susceptibility in 174 patients with ulcerative colitis (UC) cases, and 748 subjects without no lower abdominal symptoms, diarrhea or hematochezia (controls). In addition, as the second

controls, we set 360 subjects, who have an irregular bowel movement without abnormal lower endoscopic findings (IBM controls).

RESULTS

The genotype frequency of rs4268033 AA and allelic frequency of the rs4268033A allele were significantly higher in the UC cases than in both controls ($P = 0.0005$ and < 0.0001 , $P = 0.015$ and 0.0027 *vs* controls and IBM controls, respectively). Logistic regression analysis after adjustment for age and gender showed that the rs4268033 AA and rs3735656 CC genotypes were significantly associated with susceptibility to UC development (OR = 2.63, 95%CI: 1.61-4.30, $P = 0.0001$ and OR = 1.81; 95%CI: 1.12-2.94, $P = 0.015$, respectively). Similar findings were observed by the comparison with IBM controls. In addition, the rs4268033 AA genotype was significantly associated with all phenotypes of UC except early onset. There was no significant association between rs10226620 and ulcerative colitis.

CONCLUSION

Our results provide the first evidence that *MAFK* genetic polymorphisms are significantly associated with susceptibility to UC development. In particular, rs4268033 is closely associated with an increased risk for the development of UC.

Key words: Maf protein K; Genetic polymorphism; Reactive oxygen species; Ulcerative colitis; Nuclear factor-erythroid 2-related factor 2

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We investigated the association between maf protein K (*MAFK*), polymorphisms and ulcerative colitis in Japan. Both rs4268033 and rs3735656 minor allele homozygotes were significantly associated with the susceptibility to ulcerative colitis (UC) development. In addition, rs4268033 minor allele homozygote was significantly associated with all phenotypes of UC except the phenotype with younger age onset. Our results provided the first evidence that *MAFK* genetic polymorphisms were significantly associated with the susceptibility to UC development.

Arisawa T, Nakamura M, Otsuka T, Jing W, Sakurai N, Takano H, Hayashi T, Ota M, Nomura T, Hayashi R, Shimasaki T, Tahara T, Shibata T. Genetic polymorphisms of *MAFK*, encoding a small Maf protein, are associated with susceptibility to ulcerative colitis in Japan. *World J Gastroenterol* 2017; 23(29): 5364-5370 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i29/5364.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i29.5364>

INTRODUCTION

The number of inflammatory bowel disease (IBD) pa-

tients in several Asian countries, including Japan and China, has recently rapidly increased with adaptation of a westernization life style and diet^[1]. Ulcerative colitis (UC) is a representative IBD whose exact etiology is unclear, but environmental and genetic factors are implicated in its onset^[2,3]. UC is a nonspecific inflammatory disease possibly involving the colonic mucosa spanning from the rectum to the cecum. It has been clarified that the degradation of inflammation and immune response related molecules prescribed genetically participate^[4]. UC is a multifactorial, polygenic disease with probable genetic heterogeneity, and the associations between the polymorphisms of various genes and UC have been studied^[5,6].

Reactive oxygen species (ROS) are involved in promoting inflammation in various diseases, including UC^[7,8]. Nuclear factor-erythroid 2-related factor 2 (Nrf2) plays an important role in the removal of ROS^[9,10]. Nrf2 cannot induce anti-oxidant enzymes such as heme oxygenase-1 (HO-1) and peroxiredoxin 1 alone, and shows transcriptional activity when hetero-dimerized with small musculoaponeurotic fibrosarcoma (Maf)^[11]. Thus, it has been clarified that small Maf proteins are regulated transcription factors through heterodimer formation, with Nrf2 and BTB And CNC Homology 1 (Bach1)^[12], although small Mafs do not contain an obvious transcriptional activation domain^[13]. We previously reported a significant association between Nrf2 genetic polymorphisms and susceptibility to UC^[14].

In the present study, we investigated the association between genetic polymorphisms of *MAFK*, one of the small Mafs, and UC susceptibility in a Japanese population.

MATERIALS AND METHODS

Clinical samples

The study was performed using a population comprising 226 patients with UC (UC cases) and 748 subjects without lower abdominal symptoms, diarrhea or hematochezia (controls). In addition, as the second controls, we prepared 360 subjects, who have an irregular bowel movement without abnormal lower endoscopic findings (IBM controls). UC was diagnosed according to standard clinical, endoscopic, radiological, and histological criteria^[15]. Genomic DNA was isolated from peripheral blood using FlexiGene DNA Kit (QIAGEN GmbH, Hilden, Germany).

The Ethics Committees of Fujita Health University and Kanazawa Medical University approved the protocol, and written informed consent was obtained from all participating subjects.

Classification

According to their clinical courses, UC cases were classified into 2 types: continuous, or not continuous, disease (*i.e.*, relapsing or only one episode)^[16]. UC patients were also classified by endoscopic findings as total or not total colitis (left sided, distal colitis) according to the location and extension of the

Table 1 Condition of PCR and SSCP

Primer set	PCR condition	SSCP temperature
(rs4268033)		
5'-TAATCCCAACTCGCAGCA	96 °C 15 s, 60 °C	6 °C
TCTGTGT-3'	30 s, 72 °C 30 s	
5'-GGTCTGACTTAGCTGGGG	35 cycle	
AAAGTGC-3'		
(rs3735656)		
5'-ATCTCAGCGGACACAGG	96 °C 15 s, 54 °C	6 °C
CAGGA-3'	40 s, 72 °C 30 s	
5'-CTGCACTGACCACAGTTG	35 cycle	
GTGAGAA-3'		
(rs10226620)		
5'-GTCCTCCTGTGACTGGG	96 °C 15 s, 60 °C	6 °C
GCTCT-3'	30 s, 72 °C 30 s	
5'-AGGCACCACCTTGCAGGT	35 cycle	
CCTATGT-3'		

inflammatory lesions. In addition, the cases were classified into two groups according to the past highest UC disease activity index (UCDAI) during the course of the disease (≤ 8 or ≤ 9)^[17].

Selection of single nucleotide polymorphisms of *MAFK*

There are two large linkage disequilibrium blocks within 20kbp of *MAFK* with a Hardy-Weinberg equilibrium (HWE) *P* value of above 0.05 and a minor allele frequency of above 0.05. We selected rs4268033 G>A and rs3735656 T>C (*910 T>C) as a Tag single nucleotide polymorphism (SNP) in each block and another SNP, rs10226620 C>T (*1506 C>T), located in the 3'-UTR where several microRNA bind, was also selected.

Genotyping of polymorphisms

Polymorphisms were genotyped using the PCR-SSCP method as reported previously^[14,18]. The PCR and SSCP conditions are shown in Table 1. All PCR reactions were carried out in a volume of 20 μ L containing 0.1 μ g of genomic DNA using Takara HS Taq (TAKARA Bio Inc., Japan). SSCP was carried out using a GenePhor DNA separation system with GeneGel Excel 12.5/24 (GE Health Care Bio-Sciences AB, Sweden) at 6 °C temperature, and then the denatured single strand DNA bands were detected using a DNA Silver Staining Kit (GE Health Care Bio-Sciences AB).

Statistical analysis

HWE was assessed by χ^2 statistics. The age data were expressed as mean \pm SD. Mean ages between the cases and the controls was compared by Student's *t*-test, and the male/female ratio was compared by Fisher's exact test. The allele counts and the distribution of genotype were compared between the two groups by a 2 \times 2 table using Fisher's exact test. The odds ratios (OR) and 95%CI were calculated by logistic regression with adjustment for age and gender. A probability value of less than 0.05 was considered statistically significant in all analyses.

Table 2 Characteristics of the subjects and allelic frequency

	Controls	IBM controls	UC cases
Number of sample	748	360	226
Mean age \pm SD (age of onset)	57.1 \pm 17.0	58.5 \pm 14.5	40.7 \pm 14.2 ^a (33.6 \pm 13.5)
Male:female	438:310	165:195 ^b	125:101
rs4268033 G>A			
GG	366	184	101
GA	324	156	89
AA	58	20	36 ^c
A allele frequency	29.40%	27.20%	35.6% ^d
rs3735656 T>C			
TT	329	168	103
TC	346	162	90
CC	73	30	33
C allele frequency	32.90%	30.80%	34.50%
rs10226620 C>T			
CC	345	171	104
CT	328	159	94
TT	75	30	28
T allele frequency	32.00%	30.40%	33.20%

^a*P* < 0.0001 vs controls and IBM controls; ^b*P* < 0.0001 vs controls and *P* = 0.027 vs UC cases; ^c*P* = 0.0005 vs controls and *P* < 0.0001 vs IBM controls; ^d*P* = 0.015 vs controls and *P* = 0.0027 vs IBM controls. UC: Ulcerative colitis.

RESULTS

Characteristics of the study subjects and frequencies of the genotypes

The characteristics of the subjects in this study are summarized in Table 2. The mean ages of both controls and IBM controls were significantly higher than that of the UC cases. The male/female ratio of IBM controls was significantly lower than those of the controls and UC cases. Single strand DNAs of all genotypes were clearly separated by SSCP (Figure 1). The distribution of genotypes in the controls was in Hardy-Weinberg equilibrium (rs4268033, rs3735656 and rs10226620: *P* = 0.25, *P* = 0.21 and *P* = 0.87, respectively). The ratio of the mutant homozygote (AA genotype) of rs4268033 was significantly higher in the UC cases compared to the controls and IBM controls (*P* = 0.0005 and < 0.0001, respectively). However, no significant differences in the distributions of rs3735656 and rs10226620 genotypes were observed. There were no significant differences in the distributions of genotypes between the controls and IBM controls.


Association between *MAFK* polymorphisms and UC susceptibility

When the controls was compared with UC cases, logistic regression analysis after adjustment for age and gender showed that the rs4268033 mutant homozygote (AA genotype) was strongly associated with susceptibility to UC (OR = 2.63, 95%CI: 1.61-4.30, *P* = 0.0001; Table 3), and the rs3735656 mutant homozygote (CC genotype) was also significantly associated with UC susceptibility (OR = 1.81, 95%CI: 1.12-2.94, *P* = 0.015). When IBM controls was compared with UC cases, similar findings were obtained (OR = 3.54,

Table 3 Association between *MAFK* polymorphisms and ulcerative colitis

	Genotype (n)			AA vs others		Genotype (n)			CC vs others		Genotype (n)			TT vs others	
	GG	GA	AA	OR (95%CI); P value		TT	TC	CC	OR (95%CI); P value		CC	CT	TT	OR (95%CI); P value	
rs4268033 G>A															
Controls (748)	366	324	58	Reference	-										
IBM controls (358)	184	156	18	0.682	Reference										
				(0.402-1.16);											
				P = 0.16											
UC cases (226)	101	89	36	2.63	3.54										
				(1.61-4.30);	(1.82-6.88);										
				P = 0.0001	P = 0.0002										
rs3735656 T>C															
Controls (748)						329	346	73	Reference	-					
IBM controls (358)						168	162	28	0.789 (0.503-1.24);	Reference					
									P = 0.30						
UC cases (174)						103	90	33	1.81 (1.12-2.94); P	2.14					
									= 0.015	(1.16-3.95);					
										P = 0.015					
rs10226620 C>T															
Controls (748)											345	328	75	Reference	-
IBM controls (358)											171	159	28	0.764 (0.488-1.20);	Reference
														P = 0.24	
UC cases (174)											104	94	28	1.37 (0.822 - 2.28);	1.57 (0.827 -
														P = 0.23	3.00); P = 0.17

UC: Ulcerative colitis.

**Figure 1** Images of PCR-SSCP using clinical samples. Single strand DNAs were clearly separated by SSCP. The genotypes could be determined.

95%CI: 1.82-6.88, $P = 0.0002$ and OR = 2.14; 95%CI: 1.16-3.95, $P = 0.015$, for rs4268033 and rs3735656, respectively). No significant association between rs10226620 and UC was seen. The influence of *MAFK* genotypes on the symptoms from irregular bowel movement did not seem to be large.

Association between rs4268033 and UC phenotypes

The observed strong association between rs4268033 and UC susceptibility prompted us to investigate an association between this SNP and UC phenotypes. The rs4268033 genotype was only associated with UC cases with onset after 21 years of age. Regarding as clinical type, disease extension, the past history of hospitalization and the past maximum UCDAI score, rs4268033 was significantly associated with each

phenotype of UC (Table 4).

DISCUSSION

Three small Maf proteins have been identified to date: MafG, MafK and MafF were identified^[19]. These three Maf proteins have high homology and form homodimers or heterodimers with each another and also heterodimers with a group of other b-Zip proteins^[20]. Previous studies using knockout mice showed that MafG^{-/-}/K^{-/-} mice are die by the peri- or postnatal stage, whereas both MafF^{-/-}/G^{-/-} and MafF^{-/-}/K^{-/-} mice are viable and fertile^[21-23]. We therefore selected the two small Mafs, MafG and MafK, because of their apparent importance in biology. In HapMap-JPT, there are large linkage blocks of SNPs around *MAFK* but not around *MAFG*. Furthermore, previous studies revealed that MafK-Bach1 controls the expression of a subset of oxidative stress-inducible genes, such as HO-1 and ferritins^[24], whereas MafK-Nrf2 heterodimer activates their expression^[25]. We therefore suspected that *MAFK* genetic variations might affect the development and process of inflammatory diseases, including UC.

Our results provide the first evidence that *MAFK* genetic polymorphisms are significantly associated with susceptibility to UC in the Japanese population. In these polymorphisms, the rs4268033 G>A minor allele homozygote is closely associated with an increased risk for the development of UC. The allele frequencies of rs4268033 and rs10226620 in our controls, which were in HWE, were the same as that in the Japanese population reported in the HapMap database ($P = 0.73$

Table 4 Association between rs4268033 and phenotype of ulcerative colitis

	Genotype (<i>n</i>)			AA vs others OR (95%CI)	<i>P</i> value
	GG	GA	AA		
Controls (748)	366	324	58	Reference	-
Age of onset					
20 (31)	16	12	3	2.06 (0.499-8.52)	0.32
21 (176)	76	71	29	2.51 (1.51-4.19)	0.0004
Unknown (19)					
Clinical type					
Not continuous (124)	51	52	21	2.92 (1.63-5.25)	0.0003
Continuous (97)	46	36	15	2.32 (1.20-4.48)	0.012
Unknown (5)					
Extension					
Not total colitis (115)	50	46	19	2.72 (1.48-5.00)	0.0013
Total colitis (105)	49	41	15	2.18 (1.14-4.16)	0.019
Unknown (6)					
Hospitalization					
None (139)	59	59	21	2.34 (1.32-4.14)	0.0035
One time £ (76)	36	27	13	2.91 (1.42-5.97)	0.0034
Unknown (11)					
Past max. UCDAI score					
8 (135)	56	58	21	2.41 (1.36-4.27)	0.0025
9 (81)	40	27	14	3.01 (1.49-6.05)	0.002
Unknown (10)					

UC: Ulcerative colitis.

and 0.39, respectively). However, the distribution of rs3735656 genotype in our controls was different from that in HapMap-JPT ($P = 0.011$). The distribution of rs3735656 in our controls is in HWE ($P = 0.21$) whereas it is not in HapMap-JPT ($P = 0.025$). The cause of this discrepancy is unknown, but we believe that rs3735656 is worthy of further examination.

There are few reports linking *MAFK* genetic variations and clinical disease susceptibility^[26,27]. Nanashima *et al.*^[26] reported that the mutant allele of rs4720833, located in the same linkage block as rs4268033, is significantly associated with anti-tuberculosis drug induced hepatotoxicity susceptibility, whereas rs3808337, located in the same block as rs3735656, is not associated. This suggests that the rs4720833 mutant genotype might be associated with an increased risk of drug-induced injury *via* alteration of the toxicity of drug metabolites, although the detailed mechanisms remain unclear. Similarly, in our study, the rs4268033 mutant homozygote was strongly associated with UC susceptibility. In addition, this genotype was associated with all phenotypes of UC except age of onset. These findings suggest that rs4268033 may be associated with the development but not the progression of UC. The lack of association of early onset with UC may be due to the small number of cases and/or the younger controls.

It is not clear how rs4268033 participates in the development of UC. Small Maf proteins are transcription factors localized to the nucleus that dimerize with CNC family proteins, including Nrf2 and Bach1^[13]. Small Maf-Bach1 heterodimers are removed from antioxidant-responsive element (ARE) by oxidative stress, and small Maf-Nrf2 heterodimers replace and

bind to ARE, leading to the activation of antioxidant enzyme expression. Therefore, our data suggest that rs4268033 may act as a repressor for the expression of small Maf (dimerized with Nrf2) and/or as an activator for the expression of small Maf (dimerized with Bach1), resulting in association with UC susceptibility. Another possibility is that the mechanism involves the inflammatory response. Overexpression of MafK protein in T cells decreased T-cell proliferation and interleukin-2 (IL-2) secretion^[28]. Therefore, IL-2 secretion, resulting in persistent inflammation, may be increased by the diminished expression of MafK protein in the rs4268033 mutant homozygote. However, the presence of enhancers or repressors in the genome region containing the linkage block with rs4268033 remains unknown. In addition, the downregulation of Nrf2 or upregulation of Bach1 in UC patients with the rs4268033 mutant homozygote should be verified by further studies.

There are some clinical limitations in our study. We recruited patients who visited our hospital for various reasons and therefore the mean age of the controls was relatively high. Age-matched subjects with no symptom are essential for the control group. In addition, the UC treatment regimens were not standardized, possibly affecting the clinical type and extent of inflammation observed. Furthermore, we had no data on the effects of *MAFK* gene polymorphisms on the expressions of MafK protein. Our study was a case-control study and therefore further examination is necessary regarding this point. The major problem in this study is the relatively small sample size, especially the number of UC cases. A larger cohort will be required to clearly assess the association of genetic

variation with disease susceptibility. Finally, the design of this study used only samples stored at a single center and were analyzed retrospectively.

In conclusion, the present study demonstrated that *MAFK* polymorphisms are significantly associated with susceptibility to UC. In particular, the rs4268033 minor homozygote is strongly associated with increased risk for the development of UC.

COMMENTS

Background

Both environmental and genetic factors participate in the onset of ulcerative colitis (UC). Therefore, genetic alteration of inflammation related molecules may affect the susceptibility to UC.

Research frontiers

Reactive oxygen species (ROS) are involved in promoting inflammation in various diseases, including UC. Small Maf proteins are regulated transcription factors through heterodimer formation, such as nuclear factor-erythroid 2-related factor 2 which play an important role in a removal process of these ROS. Therefore, it is of interest whether genetic alteration of Maf protein K (*MAFK*), encoding small *MAFK*, may affect the susceptibility to UC.

Innovations and breakthroughs

The results provide the first evidence that *MAFK* genetic polymorphisms are significantly associated with the susceptibility to UC in the Japanese population.

Applications

MAFK single nucleotide polymorphisms should be added to the spectrum of genetic factors involved in UC in Japanese population.

Peer-review

This case control study investigated the association between genetic polymorphisms of MafK and UC susceptibility. The authors found that rs4268033 AA and rs3735656 CC genotypes were significantly associated with the susceptibility to UC.

REFERENCES

- 1 **Sakamoto N**, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, Inaba Y, Miyake Y, Sasaki S, Okamoto K, Kobashi G, Washio M, Yokoyama T, Date C, Tanaka H; Epidemiology Group of the Research Committee on Inflammatory Bowel Disease in Japan. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. *Inflamm Bowel Dis* 2005; **11**: 154-163 [PMID: 15677909 DOI: 10.1097/00054725-200502000-00009]
- 2 **Podolsky DK**. Inflammatory bowel disease. *N Engl J Med* 2002; **347**: 417-429 [PMID: 12167685 DOI: 10.1056/NEJMra020831]
- 3 **Newman B**, Siminovitch KA. Recent advances in the genetics of inflammatory bowel disease. *Curr Opin Gastroenterol* 2005; **21**: 401-407 [PMID: 15930978]
- 4 **Head KA**, Jurenka JS. Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. *Altern Med Rev* 2003; **8**: 247-283 [PMID: 12946238]
- 5 **Uniken Venema WT**, Voskuil MD, Dijkstra G, Weersma RK, Festen EA. The genetic background of inflammatory bowel disease: from correlation to causality. *J Pathol* 2017; **241**: 146-158 [PMID: 27785786 DOI: 10.1002/path.4817]
- 6 **Ye BD**, McGovern DP. Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility. *Expert Rev Clin Immunol* 2016; **12**: 1091-1107 [PMID: 27156530 DOI: 10.1080/1744666X.2016.1184972]
- 7 **Pérez S**, Taléns-Visconti R, Rius-Pérez S, Finamor I, Sastre J. Redox signaling in the gastrointestinal tract. *Free Radic Biol Med* 2017; **104**: 75-103 [PMID: 28062361 DOI: 10.1016/j.freeradbiomed.2016.12.048]
- 8 **Pravda J**. Radical induction theory of ulcerative colitis. *World J Gastroenterol* 2005; **11**: 2371-2384 [PMID: 15832404 DOI: 10.3748/wjg.v11.i16.2371]
- 9 **Ishii T**, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. *J Biol Chem* 2000; **275**: 16023-16029 [PMID: 10821856 DOI: 10.1074/jbc.275.21.16023]
- 10 **Loboda A**, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. *Cell Mol Life Sci* 2016; **73**: 3221-3247 [PMID: 27100828 DOI: 10.1007/s00018-016-2223-0]
- 11 **Itoh K**, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. *Biochem Biophys Res Commun* 1997; **236**: 313-322 [PMID: 9240432 DOI: 10.1006/bbrc.1997.6943]
- 12 **Raval CM**, Zhong JL, Mitchell SA, Tyrrell RM. The role of Bach1 in ultraviolet A-mediated human heme oxygenase 1 regulation in human skin fibroblasts. *Free Radic Biol Med* 2012; **52**: 227-236 [PMID: 22107958 DOI: 10.1016/j.freeradbiomed.2011.10.494]
- 13 **Fujiwara KT**, Kataoka K, Nishizawa M. Two new members of the maf oncogene family, mafK and mafF, encode nuclear b-Zip proteins lacking putative trans-activator domain. *Oncogene* 1993; **8**: 2371-2380 [PMID: 8361754]
- 14 **Arisawa T**, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, Fujita H, Yoshioka D, Okubo M, Sakata M, Wang FY, Hirata I, Nakano H. Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a Japanese population. *HepatoGastroenterology* 2008; **55**: 394-397 [PMID: 18613373]
- 15 **Podolsky DK**. Inflammatory bowel disease (1). *N Engl J Med* 1991; **325**: 928-937 [PMID: 1881418 DOI: 10.1056/NEJM199109263251306]
- 16 **Langholz E**, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. *Gastroenterology* 1994; **107**: 3-11 [PMID: 8020674 DOI: 10.1016/0016-5085(94)90054-X]
- 17 **Rizzello F**, Gionchetti P, Venturi A, Amadini C, Romagnoli R, Campieri M. Review article: monitoring activity in ulcerative colitis. *Aliment Pharmacol Ther* 2002; **16** Suppl 4: 3-6 [PMID: 12047252 DOI: 10.1046/j.1365-2036.16.s4.1.x]
- 18 **Arisawa T**, Tahara T, Ozaki K, Matsue Y, Minato T, Yamada H, Nomura T, Hayashi R, Matsunaga K, Fukumura A, Nakamura M, Tshikuni N, Shiroeda H, Shibata T. Association between common genetic variant of HRH2 and gastric cancer risk. *Int J Oncol* 2012; **41**: 497-503 [PMID: 22615049 DOI: 10.3892/ijo.2012.1482]
- 19 **Kataoka K**, Igarashi K, Itoh K, Fujiwara KT, Noda M, Yamamoto M, Nishizawa M. Small Maf proteins heterodimerize with Fos and may act as competitive repressors of the NF-E2 transcription factor. *Mol Cell Biol* 1995; **15**: 2180-2190 [PMID: 7891713 DOI: 10.1128/MCB.15.4.2180]
- 20 **Igarashi K**, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M. Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. *Nature* 1994; **367**: 568-572 [PMID: 8107826 DOI: 10.1038/367568a0]
- 21 **Onodera K**, Shavit JA, Motohashi H, Yamamoto M, Engel JD. Perinatal synthetic lethality and hematopoietic defects in compound mafG::mafK mutant mice. *EMBO J* 2000; **19**: 1335-1345 [PMID: 10716933 DOI: 10.1093/emboj/19.6.1335]
- 22 **Motohashi H**, Katsuoka F, Engel JD, Yamamoto M. Small Maf proteins serve as transcriptional cofactors for keratinocyte differentiation in the Keap1-Nrf2 regulatory pathway. *Proc Natl Acad Sci USA* 2004; **101**: 6379-6384 [PMID: 15087497 DOI: 10.1073/pnas.0305902101]

- 23 **Katsuoka F**, Motohashi H, Ishii T, Aburatani H, Engel JD, Yamamoto M. Genetic evidence that small maf proteins are essential for the activation of antioxidant response element-dependent genes. *Mol Cell Biol* 2005; **25**: 8044-8051 [PMID: 16135796 DOI: 10.1128/MCB.25.18.8044-8051.2005]
- 24 **Sun J**, Hoshino H, Takaku K, Nakajima O, Muto A, Suzuki H, Tashiro S, Takahashi S, Shibahara S, Alam J, Taketo MM, Yamamoto M, Igarashi K. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. *EMBO J* 2002; **21**: 5216-5224 [PMID: 12356737 DOI: 10.1093/emboj/cdf516]
- 25 **Zhang J**, Ohta T, Maruyama A, Hosoya T, Nishikawa K, Maher JM, Shibahara S, Itoh K, Yamamoto M. BRG1 interacts with Nrf2 to selectively mediate HO-1 induction in response to oxidative stress. *Mol Cell Biol* 2006; **26**: 7942-7952 [PMID: 16923960 DOI: 10.1128/MCB.00700-06]
- 26 **Nanashima K**, Mawatari T, Tahara N, Higuchi N, Nakaura A, Inamine T, Kondo S, Yanagihara K, Fukushima K, Suyama N, Kohno S, Tsukamoto K. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. *Tuberculosis (Edinb)* 2012; **92**: 253-259 [PMID: 22341855 DOI: 10.1016/j.tube.2011.12.004]
- 27 **Martínez-Hernández A**, Gutierrez-Malacatt H, Carrillo-Sánchez K, Saldaña-Alvarez Y, Rojas-Ochoa A, Crespo-Solis E, Aguayo-González A, Rosas-López A, Ayala-Sanchez JM, Aquino-Ortega X, Orozco L, Cordova EJ. Small MAF genes variants and chronic myeloid leukemia. *Eur J Haematol* 2014; **92**: 35-41 [PMID: 24118457 DOI: 10.1111/ejh.12211]
- 28 **Yoh K**, Sugawara T, Motohashi H, Takahama Y, Koyama A, Yamamoto M, Takahashi S. Transgenic over-expression of MafK suppresses T cell proliferation and function in vivo. *Genes Cells* 2001; **6**: 1055-1066 [PMID: 11737266 DOI: 10.1046/j.1365-2443.2001.00489.x]

P- Reviewer: Lakatos PL, Rong L, Swierczynski JT **S- Editor:** Qi Y
L- Editor: A **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgooffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

